High Cure Rates In A Real World Cohort Of HCV Infected Patients On Opioid Substitution Therapy (OST) Despite Alcohol And Cannabis Consumption – Data From The German Hepatitis C-Registry (DHC-R)

Author: Christensen S, Buggisch P, Mauss S, Böker KHW, Müller T, Klinker H, Zimmermann T, Serfert Y, Weber B, Reimer J, Wedemeyer H , German Hepatitis C-Registry

Theme: Clinical Research Year: 2018

Background: People who inject drugs (PWID) are most affected by HCV infection. In Germany, 80% of n=4,368 newly diagnosed with positive HCV-RNA were PWID (2016). To reach the WHO goal of HCV eradication by 2030, DAA therapy has to be scaled up especially in PWID. Methods: The DHC-R is a national real-world registry study. N=7,747 chronic HCV patients started DAA therapy: n=739 OST patients (Opioid Substitution Therapy), n= 1,500 non-OST/DU: patients with former/current Drug Use without OST and n=5,508 non-OST/NDU: patients without a history of drug use (Non Drug Use). Therapy completed and at least one follow-up documentation (Intention-to-treat (ITT) population): N=528 OST and n=5,582 non-OST (DU and NDU). Results: 17.3% (128/739) of OST, 17.1% (256/1,500) of non-OST/DU and in 11.3% (631/5,508) of non-OST/NDU patients reported alcohol consumption. In non-OST/NDU, significantly less patients (13.9%, 88/631) consumed high amounts of alcohol [(>40g alcohol/d (men)/>30g/d (women)] when compared to OST 25% (32/128) or non-OST/DU 22.2% (57/256) patients (p

Download abstract Download Poster